ArticleBone2015
Targeted delivery of mesenchymal stem cells to the bone.
Article in Bone, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus.Human gene therapy · 2024Review
- Mesenchymal Stem Cells Coated with Synthetic Bone-Targeting Polymers Enhance Osteoporotic Bone Fracture Regeneration.Bioengineering (Basel, Switzerland) · 2020Article
- Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing.Current osteoporosis reports · 2020Review
- Osteoblast-Based Therapy-A New Approach for Bone Repair in Osteoporosis: Pre-Clinical Setting.Tissue engineering and regenerative medicine · 2020Article
- MiR-155 inhibition alleviates suppression of osteoblastic differentiation by high glucose and free fatty acids in human bone marrow stromal cells by upregulating SIRT1.Pflugers Archiv : European journal of physiology · 2020Article
- Role of nanoparticles in osteogenic differentiation of bone marrow mesenchymal stem cells.Cytotechnology · 2020Article
- Imaging of a high concentration of iron labeled cells with positive contrast in a rat knee.Magnetic resonance in medicine · 2019Article
- Mesenchymal Stromal Cell-Based Bone Regeneration Therapies: From Cell Transplantation and Tissue Engineering to Therapeutic Secretomes and Extracellular Vesicles.Frontiers in bioengineering and biotechnology · 2019Review
- Prevalence of glucocorticoid induced osteonecrosis in the mouse is not affected by treatments that maintain bone vascularity.Bone reports · 2018Article
- Mesenchymal Stem Cell Therapy for Bone Regeneration.Clinics in orthopedic surgery · 2018Review
- Positive contrast from cells labeled with iron oxide nanoparticles: Quantitation of imaging data.Magnetic resonance in medicine · 2017Article
- Bone-seeking agents for the treatment of bone disorders.Drug delivery and translational research · 2017Review
- A nanofibrous electrospun patch to maintain human mesenchymal cell stemness.Journal of materials science. Materials in medicine · 2017Article
- Differential analysis of genome-wide methylation and gene expression in mesenchymal stem cells of patients with fractures and osteoarthritis.Epigenetics · 2017Article
- A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis.Calcified tissue international · 2017Article
- Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates.Pharmaceutics · 2016Review
- EGCG ameliorates the hypoxia-induced apoptosis and osteogenic differentiation reduction of mesenchymal stem cells via upregulating miR-210.Molecular biology reports · 2016Article
- IGF-1 Receptor Insufficiency Leads to Age-Dependent Attenuation of Osteoblast Differentiation.Endocrinology · 2015Article
- Engineering mesenchymal stem cells for regenerative medicine and drug delivery.Methods (San Diego, Calif.) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.